FXR

Cat. No.

A12652

CAS No.

293754-55-9

T0901317

T0901317 is a potent and selective agonist for LXR and FXR, with EC50s of 50 nM and 5 μM, respectively

Cat. No.

A11141

CAS No.

278779-30-9

GW4064

GW4064 is a selective, non-steroidal farnesoid X receptor (FXR) agonist (EC50 = 15 nM).

Cat. No.

A11186

CAS No.

629664-81-9

Turofexorate isopropyl (WAY-362450)

Synonyms: WAY362450; XL335

WAY-362450 is a highly potent, selective, and orally bioavailable farnesoid X receptor (FXR) agonist (EC50: 4 nM, eff=149%).

Cat. No.

A13866

CAS No.

459789-99-2

Obeticholic Acid

Synonyms: INT-747; 6-ECDCA

Obeticholic Acid is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM

Cat. No.

A13143

CAS No.

1418274-28-8

Cilofexor

Synonyms: GS-9674

Cilofexor (GS-9674) is a farnesoid X receptor (FXR) agonist.

Cat. No.

A12547

CAS No.

434-13-9

Lithocholic acid

Lithocholic acid is a bile acid that acts as a detergent to solubilize fats for absorption.

Cat. No.

A12625

CAS No.

1773489-72-7

Nidufexor

Nidufexor is a farnesoid X receptor (FXR) agonist.

Cat. No.

A16968

CAS No.

1383816-29-2

Tropifexor

Synonyms: LJN452

Tropifexor, also known as LJN452, is a farnesoid X receptor agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).

Cat. No.

A16997

CAS No.

1268244-85-4

PX20606 trans-isomer

Synonyms: PX-20606; PX-102; PX10

PX20606, also known as PX-102, is a FXR agonist. It induces high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.

Cat. No.

A16999

CAS No.

1268244-88-7

Px-104

Synonyms: Px-102

Px-104, also known as Px-102, is a farnesoid X receptor (FXR) agonist potentially for the treatment of non-alcoholic fatty liver disease.

Cat. No.

A17016

CAS No.

1103500-20-4

LY2562175

LY2562175 is a potent and selective FXR agonist in vitro and has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species.

Cat. No.

A20433

CAS No.

1612191-86-2

BAR502

BAR502 is a dual FXR and GPBAR1 agonist with IC50 values of 2 μM and 0.4 μM, respectively.

Cat. No.

A21494

CAS No.

1000403-03-1

INT-767

INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC50s of 30 and 630 nM, respectively.

Cat. No.

A21771

CAS No.

574013-66-4

Fexaramine

Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity relative to natural compounds.

Cat. No.

A36250

CAS No.

1933507-63-1

EDP-305

EDP-305 is a highly selective agonist of the farnesoid X receptor (FXR), exhibiting potent activity with EC50 values of 34 nM in chimeric FXR and 8 nM in full-length FXR. This compound demonstrates significant antifibrotic effects, making it a valuable tool for studying liver diseases. EDP-305 is relevant in research focused on primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH).

Cat. No.

A39656

CAS No.

2253764-93-9

Cilofexor tromethamine

Synonyms: GS-9674 tromethamine

Cilofexor tromethamine is a nonsteroidal agonist of the farnesoid X receptor (FXR), primarily targeting liver diseases. It demonstrates significant potential in improving markers of cholestasis and liver injury, making it a valuable reagent in research for conditions such as primary sclerosing cholangitis. Cilofexor tromethamine has exhibited a favorable safety profile in clinical studies involving patients without cirrhosis, leading to notable enhancements in liver biochemical parameters and cholestatic markers.

Cat. No.

A50910

CAS No.

1192171-69-9

Vonafexor

Synonyms: EYP001

Vonafexor is a selective agonist of the farnesoid X receptor (FXR), offering an oral bioavailability profile. This compound has demonstrated substantial reductions in HBsAg levels when used in conjunction with Peg-IFNα. Vonafexor is primarily employed in anti-HBV research, making it a valuable reagent for studies focused on hepatitis B virus therapies.

Cat. No.

A54021

CAS No.

3107769-23-0

FXR agonist 17

FXR agonist 17 functions as a steroidal agonist of the farnesoid X receptor (FXR), exhibiting EC50 values of 42.2 nM in TR-FRET assays and 176.4 nM in luciferase reporter assays. This compound also activates TGR5 with an EC50 of 2.6 μM while showing no activation of hMRGPRX4. FXR agonist 17 demonstrates significant biological activity through its anti-inflammatory, hepatoprotective, and antifibrotic properties, contributing to the reduction of non-alcoholic steatohepatitis (NAFLD) activity scores and alleviating liver fibrosis severity. It serves as a valuable tool for research into NAFLD, cholestatic liver disease, and liver fibrosis.

Cat. No.

A60387

CAS No.

2898-95-5

Ursodeoxycholic acid sodium

Synonyms: Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium

Ursodeoxycholic acid sodium is a potent agonist of the G-protein coupled receptor 19 (GPCR19) and antagonist of the farnesoid X receptor (FXR). This secondary bile acid plays a crucial role in maintaining intestinal barrier integrity and regulating lipid metabolism. Its ability to modulate bile acid-activated receptors makes it valuable for investigating various hepatic and gastrointestinal diseases. Ursodeoxycholic acid sodium is also orally active, making it suitable for diverse in vitro and in vivo research applications.

Cat. No.

A69466

CAS No.

2226133-29-3

HPG1860

HPG1860 is a highly selective and potent agonist of the farnesoid X receptor (FXR), demonstrating an EC50 of 18 nM in FXR-luciferase reporter assays. This compound exhibits minimal activity on TGR5 and 13 other related nuclear receptors, with EC50 values exceeding 30.0 μM. HPG1860 is primarily utilized in research investigating non-alcoholic steatohepatitis (NASH) and related metabolic disorders.

Cat. No.

A69815

CAS No.

2477873-64-4

BMS-986339

BMS-986339 is a potent agonist of the farnesoid X receptor (FXR), demonstrating oral bioactivity. This compound interacts with key residues, including His298 and Asn287, to exert its biological effects. BMS-986339 is utilized in research focusing on primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), making it valuable for studies related to anti-fibrotic pathways.

Cat. No.

A70735

CAS No.

863239-61-6

Tauro-obeticholic acid

Tauro-obeticholic acid is an active metabolite of obeticholic acid, functioning as a potent farnesoid-X receptor (FXR) agonist. This compound exhibits significant biological activity in the regulation of bile acid homeostasis and lipid metabolism. It is primarily utilized in research exploring metabolic disorders, liver diseases, and potential therapeutic interventions targeting FXR pathways.

Cat. No.

A71439

CAS No.

566-24-5

Isochenodeoxycholic acid

Synonyms: isoCDCA

Isochenodeoxycholic acid (isoCDCA) is a potent farnesoid X receptor (FXR) agonist. It effectively activates FXR and enhances the mRNA expression of target genes such as Ostβ and Kng1. Isochenodeoxycholic acid is also a substrate for the liver class I ADH γγ isozyme, facilitating the 3β-dehydrogenation reaction. This compound is valuable for research in metabolic processes and FXR-related signaling pathways.

Cat. No.

A74868

CAS No.

59274-67-8

Deoxycholic acid 3-O-β-D-glucuronide disodium

Deoxycholic acid 3-O-β-D-glucuronide disodium is a potent agonist of the farnesoid X receptor (FXR). This compound has been shown to play a significant role in regulating bile acid homeostasis, lipid metabolism, and glucose metabolism. Its applications include the study of metabolic disorders, liver diseases, and potential therapeutic strategies targeting FXR signaling pathways.

Cat. No.

A74870

CAS No.

3037847-72-3

FXR agonist 3

FXR Agonist 3 is a potent farnesoid X receptor (FXR) agonist, designed for the treatment of non-alcoholic steatohepatitis (NASH). This compound effectively inhibits the expression of COL1A1, TGF-β1, α-SMA, and TIMP1, showcasing significant anti-fibrogenic properties. Additionally, FXR Agonist 3 markedly reduces liver steatosis and inflammation while improving levels of liver fibrosis, making it a valuable tool in liver disease research.